Table 1. Clinical characteristics of patients.
| Bevacizumab group N=24 | Chemotherapy group N=18 | |
|---|---|---|
|
Sex | ||
| M | 16 (67%) | 15 (83%) |
| F |
8 (33%) |
3 (17%) |
|
Age | ||
| Median | 60 | 64 |
| Range |
33–74 |
45–67 |
|
ECOG PS | ||
| 0 | 19 (79%) | 16 (89%) |
| 1 |
5 (21%) |
2 (11%) |
|
Primary tumour | ||
| Colon | 18 (75%) | 17 (94%) |
| Rectum |
6 (25%) |
1 (6%) |
|
Previous adjuvant CT | ||
| Yes | 2 (8%) | 4 (22%) |
| No |
22 (92%) |
14 (73%) |
|
Time to metastases | ||
| Metachronous | 3 (12%) | 6 (33%) |
| Synchronous |
21 (88%) |
12 (67%) |
|
Liver-only metastases | ||
| Yes | 19 (79%) | 18 (100%) |
| No |
5 (21%) |
0 (0%) |
|
Cycles of conversion therapy | ||
| Median (range) |
8 (4–12) |
12 (8–12) |
|
No. of resected lesions | ||
| Median (range) |
3 (1–10) |
3 (1–9) |
|
Diameter per lesion at resection | ||
| Medium |
3.5 cm |
3.0 cm |
|
Postresection treatment | ||
| Yes | 17 (71%) | 2 (11%) |
| No | 7 (29%) | 16 (89%) |
Abbreviations: CT=chemotherapy; ECOG PS=Eastern Cooperative Oncology Group Performance Status; F=female; M=male.